Yaohan Zhou , Zhengping Li , Guoqing Liu , Zhenping Chen , Wanru Yao , Gang Li , Yingzi Zhen , Xiaoling Cheng , Di Ai , Kun Huang , Wang Cao , Runhui Wu MD, PhD
{"title":"Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Moderate or Severe Hemophilia A in China","authors":"Yaohan Zhou , Zhengping Li , Guoqing Liu , Zhenping Chen , Wanru Yao , Gang Li , Yingzi Zhen , Xiaoling Cheng , Di Ai , Kun Huang , Wang Cao , Runhui Wu MD, PhD","doi":"10.1016/j.clinthera.2024.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>It is still being determined if prophylaxis (PR) has superior cost effectiveness compared with on-demand (OD) treatment for moderate or severe hemophilia A (HA) children in China.</div></div><div><h3>Objective/Purpose</h3><div>To evaluate the cost-effectiveness of PR and OD treatment for children with moderate or severe HA without inhibitors in China.</div></div><div><h3>Methods</h3><div>A retrospective cost-effectiveness study was conducted on 640 HA children (373 and 267 children were on the PR and OD treatment, respectively) from January 2021 to November 2022. The Markov model was used to estimate the economic and clinical outcomes and would run for 17 yearly cycles with the initial age at 2 years. The transfer probabilities were extracted from the data of “Hemophilia Home Care Center” and the literature published. All patients’ drug costs were collected from the data of “Hemophilia Home Care Center”. One-way and probabilistic sensitivity analyses were conducted on the data to evaluate the robustness of the results.</div></div><div><h3>Results/Findings</h3><div>PR was consistently associated with higher overall quality-adjusted life years (QALYs) compared with OD treatment (9.59 QALYs vs. 6.85 QALYs). The incremental cost-effectiveness ratio (ICER) of PR compared with the OD treatment was calculated to be approximately US$12,151.35 (RMB¥81,778.55) per QALY gained. This amount was lower than the willingness-to-pay (WTP) threshold of US$38,212.74 (RMB¥257,171.71). One-way sensitivity analysis found that the results were sensitive to the cost of OD and PR treatments.</div></div><div><h3>Conclusions/Implications</h3><div>This study indicated that PR is cost-effective compared with OD treatment for children with moderate or severe HA without inhibitors in China.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"46 12","pages":"Pages 1010-1015"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291824002662","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
It is still being determined if prophylaxis (PR) has superior cost effectiveness compared with on-demand (OD) treatment for moderate or severe hemophilia A (HA) children in China.
Objective/Purpose
To evaluate the cost-effectiveness of PR and OD treatment for children with moderate or severe HA without inhibitors in China.
Methods
A retrospective cost-effectiveness study was conducted on 640 HA children (373 and 267 children were on the PR and OD treatment, respectively) from January 2021 to November 2022. The Markov model was used to estimate the economic and clinical outcomes and would run for 17 yearly cycles with the initial age at 2 years. The transfer probabilities were extracted from the data of “Hemophilia Home Care Center” and the literature published. All patients’ drug costs were collected from the data of “Hemophilia Home Care Center”. One-way and probabilistic sensitivity analyses were conducted on the data to evaluate the robustness of the results.
Results/Findings
PR was consistently associated with higher overall quality-adjusted life years (QALYs) compared with OD treatment (9.59 QALYs vs. 6.85 QALYs). The incremental cost-effectiveness ratio (ICER) of PR compared with the OD treatment was calculated to be approximately US$12,151.35 (RMB¥81,778.55) per QALY gained. This amount was lower than the willingness-to-pay (WTP) threshold of US$38,212.74 (RMB¥257,171.71). One-way sensitivity analysis found that the results were sensitive to the cost of OD and PR treatments.
Conclusions/Implications
This study indicated that PR is cost-effective compared with OD treatment for children with moderate or severe HA without inhibitors in China.
期刊介绍：
Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
